Overview

Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Desvenlafaxine Succinate